BDKRB1 and age-related macular degeneration: Our study provides compelling evidence that B1R antagonist treatment can inhibit inflammation, neovascularization, and angiogenesis in addition to restoring the photoreceptor and bipolar cell function in the retina of a preclinical mouse model of AMD.